Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE offers an innovative new option for patients with moderate-to-severe plaque psoriasis to address patients cycling on...
Hence then, the article about fda approval of icotyde icotrokinra ushers in new era for first line systemic treatment of plaque psoriasis with a targeted oral peptide was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide )
Also on site :
- Amazon's ‘Supportive’ Skechers Wedge Sandals Are ‘Great for Traveling’ and Just $31 Before the Big Spring Sale
- Physicl stellt auf der NVIDIA GTC die Dateninfrastrukturschicht für Physical AI vor
- CometChat Secures $6.5M in Strategic Funding from Run Ventures to Expand Next-Generation AI Agent Platform